CATALOGO DEI PRODOTTI DELLA RICERCA

PILOTTO, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.590
EU - Europa 3.477
AS - Asia 2.055
AF - Africa 54
SA - Sud America 26
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 5
AN - Antartide 1
Totale 9.214
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.564
CN - Cina 1.197
GB - Regno Unito 953
SG - Singapore 610
IT - Italia 467
RU - Federazione Russa 436
SE - Svezia 424
IE - Irlanda 367
FR - Francia 320
DE - Germania 223
FI - Finlandia 129
KR - Corea 45
TG - Togo 42
UA - Ucraina 42
VN - Vietnam 39
HK - Hong Kong 34
ID - Indonesia 33
PL - Polonia 26
NL - Olanda 24
JP - Giappone 22
BE - Belgio 20
CA - Canada 17
IN - India 15
IR - Iran 13
CZ - Repubblica Ceca 12
AZ - Azerbaigian 7
BR - Brasile 7
CL - Cile 7
TR - Turchia 7
CH - Svizzera 6
EU - Europa 5
PH - Filippine 5
AU - Australia 4
EG - Egitto 4
ES - Italia 4
KG - Kirghizistan 4
MA - Marocco 4
PE - Perù 4
RO - Romania 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
AM - Armenia 3
AT - Austria 3
CO - Colombia 3
DK - Danimarca 3
EC - Ecuador 3
LK - Sri Lanka 3
LV - Lettonia 3
SK - Slovacchia (Repubblica Slovacca) 3
BM - Bermuda 2
CR - Costa Rica 2
IL - Israele 2
LA - Repubblica Popolare Democratica del Laos 2
LU - Lussemburgo 2
LY - Libia 2
MX - Messico 2
MY - Malesia 2
NO - Norvegia 2
PA - Panama 2
PT - Portogallo 2
SA - Arabia Saudita 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
BG - Bulgaria 1
BO - Bolivia 1
GR - Grecia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
JM - Giamaica 1
KH - Cambogia 1
KZ - Kazakistan 1
NZ - Nuova Zelanda 1
TM - Turkmenistan 1
Totale 9.214
Salva come PNG Salva come JPEG
Città #
Southend 901
Chandler 819
Singapore 533
Dublin 367
Woodbridge 297
Ashburn 271
Beijing 258
Jacksonville 195
Ann Arbor 181
Verona 134
Lawrence 125
Princeton 125
Wilmington 114
New York 106
Jinan 102
Houston 73
Sindelfingen 64
Redmond 59
Shenyang 58
Nanjing 54
Tianjin 53
Hebei 50
Helsinki 46
Seoul 45
Lomé 42
Seattle 37
Washington 33
Santa Clara 32
Kent 31
Nanchang 31
Jakarta 30
Milan 30
Haikou 29
Hangzhou 28
Hong Kong 28
Zhengzhou 27
Changsha 25
Ningbo 25
Boardman 24
Guangzhou 23
Dong Ket 22
Los Angeles 21
Brussels 20
Taizhou 20
Dallas 19
Moscow 19
Munich 19
Falls Church 18
Taiyuan 18
Tokyo 18
Jiaxing 17
Redwood City 16
Rome 16
Fuzhou 13
Norwalk 13
Amsterdam 12
Bologna 12
Brno 12
Augusta 11
Lanzhou 11
San Francisco 11
Padova 10
Lancaster 9
Lappeenranta 9
Toronto 9
Trento 9
San Mateo 8
Este 7
Frankfurt am Main 7
London 7
Baku 6
Chicago 6
Dearborn 6
Dongguan 6
Paris 6
Ardabil 5
Bussolengo 5
Clearwater 5
Fairfield 5
Isola della Scala 5
Kochi 5
Menlo Park 5
Shanghai 5
Bishkek 4
Boydton 4
Brugnera 4
Cagliari 4
Cambridge 4
Council Bluffs 4
Falkenstein 4
Fremont 4
Lima 4
Lozzo Atestino 4
Monmouth Junction 4
Ottawa 4
Quanzhou 4
Tashkent 4
Zanjan 4
Andover 3
Cairate 3
Totale 6.054
Salva come PNG Salva come JPEG
Nome #
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis 154
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 140
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 125
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 125
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 121
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations 119
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 110
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 109
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 108
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 105
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 105
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 103
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 100
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 100
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 97
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 97
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 95
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 95
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 92
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 92
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 91
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 89
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 88
Clinical meta-analyses of targeted therapies in adenocarcinoma. 86
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 84
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 79
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 79
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 79
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC 79
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 78
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 78
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 76
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 75
Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease 75
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 74
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 73
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 72
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients 72
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 72
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 70
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 69
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 69
Do immune checkpoint inhibitors need new studies methodology? 69
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer 68
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 68
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 68
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 67
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 65
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 65
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 65
Muscle derangement and alteration of the nutritional machinery in NSCLC 64
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 64
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 63
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 63
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 63
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 63
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials 62
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 62
Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'? 61
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 61
Physical activity and exercise in lung cancer care: will promises be fulfilled? 61
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. 60
Exercise levels and preferences in cancer patients: a cross-sectional study 60
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 60
Factors influencing physical activity in cancer patients during oncological treatments: a qualitative study 60
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 60
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 60
Sorafenib for lung cancer: is the "Battle" still open ? 59
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 59
Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer. 58
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 58
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. 57
Genetic, epigenetic and micro-environmental markers as predictors of prognosis, response and resistance to chemotherapy, targeted agents and immunotherapy in resected squamous cell lung carcinoma (SQLC). 57
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm 56
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma 56
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 55
Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 54
Cellular and molecular biology of small cell lung cancer: an overview 53
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations 53
mTOR Cross-Talk in Cancer and Potential for Combination Therapy. 53
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC) 53
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 53
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option? 52
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. 52
Nurses' perspectives on physical activity promotion in cancer patients: A qualitative research 52
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 51
A multimodal approach to cancer-related cachexia: from theory to practice 51
Exercise oncology: It is time to make a change 51
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 50
Exercise and anemia in cancer patients: could make the difference? 50
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 49
Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening 48
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives 48
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 47
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 47
Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy? 47
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 46
Melanoma: oncogenic drivers and the immune system 46
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives 46
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer. 45
Totale 7.193
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.343
article - articoli 42.341
book - libri 0
conference - conferenze 603
curatela - curatele 0
other - altro 178
patent - brevetti 0
selected - selezionate 0
volume - volumi 221
Totale 86.686
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020512 0 0 0 0 91 51 85 35 52 63 51 84
2020/2021815 92 127 35 112 99 88 29 16 24 24 122 47
2021/20221.080 60 292 8 119 39 27 31 58 46 23 95 282
2022/20232.327 144 261 206 411 196 539 19 137 262 21 97 34
2023/20241.661 59 95 158 166 212 267 99 139 39 117 229 81
2024/20251.553 230 184 209 791 139 0 0 0 0 0 0 0
Totale 9.494